Gilead Sciences Inc (NASDAQ:GILD)

U.S. Markets are not yet open, but GILD is being traded in the pre-market session. Pre-Market quote »
115.04
Delayed Data
As of Jul 02
 -0.97 / -0.84%
Today’s Change
84.75
Today|||52-Week Range
123.37
+22.05%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$169.1B

Company Description

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Its primary areas of focus include primary areas of focus include human immunodeficiency virus (HIV), liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection, oncology and inflammation, and serious cardiovascular and respiratory conditions. Gilead Sciences was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Contact Information

Gilead Sciences, Inc.
333 Lakeside Drive
Foster City California 94404
P:(650) 574-3000
Investor Relations:
(650) 522-1936

Employees

Shareholders

Mutual fund holders47.05%
Other institutional39.56%
Individual stakeholders1.07%

Top Executives

John C. MartinChairman & Chief Executive Officer
John F. MilliganPresident & Chief Operating Officer
Robin L. WashingtonChief Financial Officer & Executive Vice President
Norbert W. BischofbergerChief Scientific Officer & Executive VP-Research
Gregg H. AltonSecretary, EVP-Corporate & Medical Affairs

To view my watchlist

Not a member yet?

Sign up now for a free account